Study #2019-0469
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
MD Anderson Study Status
Not Accepting
Treatment Agent
zanubrutinib, rituximab, bendamustine
Description
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mantle Cell Lymphoma, Non-Hodgkin Lymphoma
Study phase:
Phase III
Physician name:
Preetesh Jain
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-888-912-0153
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.